Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.

Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R, Cascinu S.

Cancer Metastasis Rev. 2014 Mar;33(1):321-31. doi: 10.1007/s10555-013-9453-5. Review.


von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R.

J Urol. 2008 Sep;180(3):860-5; discussion 865-6. doi: 10.1016/j.juro.2008.05.015. Epub 2008 Jul 17.


Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM.

BJU Int. 2006 Oct;98(4):756-62. Epub 2006 Jul 7.


Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.

Golshayan AR, Brick AJ, Choueiri TK.

Future Oncol. 2008 Feb;4(1):85-92. doi: 10.2217/14796694.4.1.85. Review.


Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.

Audenet F, Yates DR, Cancel-Tassin G, Cussenot O, Rouprêt M.

BJU Int. 2012 Jun;109(12):1864-70. doi: 10.1111/j.1464-410X.2011.10661.x. Epub 2011 Oct 28. Review.


Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.

Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naïmi B, Porcher R, de La Taille A, Menashi S, Calvo F, Mourah S.

PLoS One. 2010 May 19;5(5):e10715. doi: 10.1371/journal.pone.0010715.


VEGF-targeted therapy in metastatic renal cell carcinoma.

Rini BI.

Oncologist. 2005 Mar;10(3):191-7. Review. Retraction in: Oncologist. 2011;16(10):1481.


Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.

Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K.

Oncol Rep. 2005 May;13(5):859-64.


Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.

Gunningham SP, Currie MJ, Han C, Turner K, Scott PA, Robinson BA, Harris AL, Fox SB.

Cancer Res. 2001 Apr 1;61(7):3206-11.


VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.

Rathmell WK, Chen S.

Expert Rev Anticancer Ther. 2008 Jan;8(1):63-73. Review.


Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.

Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER.

Cancer Res. 2001 Oct 1;61(19):7277-81.


Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.

Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, Escudier B, Azzarone B, Caignard A.

Oncogene. 2011 Jun 9;30(23):2622-32. doi: 10.1038/onc.2010.638. Epub 2011 Jan 24.


Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.

Cancer Res. 2002 Jul 1;62(13):3803-11.


Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease.

Campbell L, Al-Jayyoussi G, Gutteridge R, Gumbleton N, Griffiths R, Gumbleton S, Smith MW, Griffiths DF, Gumbleton M.

J Transl Med. 2013 Oct 11;11:255. doi: 10.1186/1479-5876-11-255.


Metastatic renal cell carcinoma: many treatment options, one patient.

Rini BI.

J Clin Oncol. 2009 Jul 1;27(19):3225-34. doi: 10.1200/JCO.2008.19.9836. Epub 2009 May 26. Review.


The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.

Clark PE.

Kidney Int. 2009 Nov;76(9):939-45. doi: 10.1038/ki.2009.296. Epub 2009 Aug 5. Review.


The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG Jr, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF.

Mol Cell Biol. 1999 Sep;19(9):5902-12.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk